Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Arturo Vega-Ruiz

Secondary Myelodysplastic Syndrome in a Patient With Philadelphia-Positive Acute Lymphoblastic Leukemia After Achieving a Major Molecular Response With hyperCVAD Plus Imatinib Mesylate

Leukemia Research

English

Related publications

Therapy With Imatinib Mesylate (Glivec) Preceding Allogeneic Stem Cell Transplantation (SCT) in Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

English

A Novel BCR-ABL1 Mutation in a Patient With Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia

OncoTargets and Therapy

Oncology

Pharmacology

2018

English

Efficacy and Safety of Imatinib Mesylate (Glivec™) in Combination With Interferon-Α (IFN-α) in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

English

A Pathway-Based Gene Signature Correlates With Therapeutic Response in Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

English

Development of Multiple Myeloma in a Patient With Chronic Myeloid Leukemia After Treatment With Imatinib Mesylate

English

Secondary Philadelphia Chromosome Acquired During Therapy of Acute Leukemia and Myelodysplastic Syndrome

English

Pcn137 - The Economic Evaluation of Imatinib Combined With Chemotherapy for Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in China

English

Three‑way Philadelphia Translocation T(9;10;22)(q34;p11.2;q11.2) as a Secondary Abnormality in an Imatinib Mesylate‑resistant Chronic Myeloid Leukemia Patient

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Arturo Vega-Ruiz

Secondary Myelodysplastic Syndrome in a Patient With Philadelphia-Positive Acute Lymphoblastic Leukemia After Achieving a Major Molecular Response With hyperCVAD Plus Imatinib Mesylate

Related publications

Therapy With Imatinib Mesylate (Glivec) Preceding Allogeneic Stem Cell Transplantation (SCT) in Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

A Novel BCR-ABL1 Mutation in a Patient With Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia

Efficacy and Safety of Imatinib Mesylate (Glivec™) in Combination With Interferon-Α (IFN-α) in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

A Pathway-Based Gene Signature Correlates With Therapeutic Response in Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Development of Multiple Myeloma in a Patient With Chronic Myeloid Leukemia After Treatment With Imatinib Mesylate

Secondary Philadelphia Chromosome Acquired During Therapy of Acute Leukemia and Myelodysplastic Syndrome

Pcn137 - The Economic Evaluation of Imatinib Combined With Chemotherapy for Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in China

Three‑way Philadelphia Translocation T(9;10;22)(q34;p11.2;q11.2) as a Secondary Abnormality in an Imatinib Mesylate‑resistant Chronic Myeloid Leukemia Patient